Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Mar;19(3):149.
doi: 10.1038/s41571-022-00604-6.

Survival benefit with second-line combination in endometrial cancer

Diana Romero  1
Affiliations
Comment

Survival benefit with second-line combination in endometrial cancer

Diana Romero. Nat Rev Clin Oncol. 2022 Mar.
No abstract available

PubMed Disclaimer

Comment on

  • Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
    Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D; Study 309–KEYNOTE-775 Investigators. Makker V, et al. N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19. N Engl J Med. 2022. PMID: 35045221 Free PMC article. Clinical Trial.

References

Original article
    1. Makker, V. et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2108330 (2022). - DOI - PubMed

LinkOut - more resources